Achaogen Stock

Achaogen ROE

Delisted

The Return on Equity (ROE) of Achaogen (AKAOQ) as of Aug 13, 2026 is 2,966.63 %. In the previous year, Return on Equity (ROE) was -103.00 % — a change of -2,980.29% (higher).

ROE

2,966.63 %

YoY

-2,980.29%

Last updated:

In 2026, Achaogen's return on equity (ROE) was 2,966.63 %, a -2,980.29% increase from the -103.00 % ROE in the previous year.

Access this data via the Eulerpool API

Achaogen Stock analysis

What does Achaogen do? Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.

ROE Details

Decoding Achaogen's Return on Equity (ROE)

Achaogen's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Achaogen's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Achaogen's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Achaogen’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Achaogen stock

Return on Equity (ROE) of Achaogen is 2,966.63 % in 2026.

Return on Equity (ROE) of Achaogen changed from -103.00 % to 2,966.63 %, representing a -2,980.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Achaogen since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Achaogen with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Achaogen

All Key Metrics — Achaogen